Showing results (1-10 of 26) with videos related to
Sort By:
Pageof 3
Clinical Sarcoma Research|December 12, 2018
Extraskeletal myxoid chondrosarcoma with massive pulmonary metastasesLuca Paoluzzi, Munir GhesaniBiodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|April 1, 2006
Mechanistic rationale and clinical evidence for the efficacy of proteasome inhibitors against indolent and mantle cell lymphomasLuca Paoluzzi, Owen A O'ConnorCancer Biology & Therapy|May 12, 2004
Histone deacetylase inhibitors are potent radiation protectantsLuca Paoluzzi, William D FiggAdvances in Experimental Medicine and Biology|October 6, 2010
Targeting survival pathways in lymphomaLuca Paoluzzi, Owen A O'ConnorCurrent Oncology (Toronto, Ont.)|January 22, 2021
Safe Administration of Cemiplimab to a Kidney Transplant Patient with Locally Advanced Squamous Cell Carcinoma of the ScalpLuca Paoluzzi, Thomas J OwJAMA Oncology|October 23, 2018
Diagnosis, Prognosis, and Treatment of Alveolar Soft-Part Sarcoma: A ReviewLuca Paoluzzi, Robert G MakiHematology/Oncology Clinics of North America|October 29, 2008
New drugs for the treatment of lymphomaLuca Paoluzzi, Yukiko Kitagawa, Matko Kalac, et al.British Journal of Haematology|July 17, 2009
The anti-histaminic cyproheptadine synergizes the antineoplastic activity of bortezomib in mantle cell lymphoma through its effects as a histone deacetylase inhibitorLuca Paoluzzi, Luigi Scotto, Enrica Marchi, et al.Clinical Lymphoma, Myeloma & Leukemia|August 23, 2011
Bortezomib-induced tumor lysis syndrome in a patient with HIV-negative plasmablastic lymphomaMark Lipstein, Owen O'Connor, Francesca Montanari, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 14, 2010
Romidepsin and belinostat synergize the antineoplastic effect of bortezomib in mantle cell lymphomaLuca Paoluzzi, Luigi Scotto, Enrica Marchi, et al.Pageof 3